Quest Diagnostics and Mass General Brigham Launch Clinical Trials to Evaluate Haystack MRD ctDNA for Post-Surgical Cancer Treatment
Reuters
Aug 07
Quest Diagnostics and Mass General Brigham Launch Clinical Trials to Evaluate Haystack MRD ctDNA for Post-Surgical <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>
Quest Diagnostics Incorporated has announced a new research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital. This collaboration will focus on two clinical trials investigating the use of Haystack MRD™, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease test. The trials aim to evaluate its effectiveness as a tool for postoperative therapy decisions in cases of cutaneous squamous cell carcinoma and HPV-independent head and neck squamous cell carcinoma. Led by Dr. Dan Faden and co-led by Sophia Shalhout, PhD, and Kevin Emerick, MD, the trials will assess Haystack MRD's impact on risk stratification and early detection of residual disease. Results of these studies have not yet been presented and will be available in the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: NY43861) on August 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.